Researchers from institutions across the U.S. evaluated data from the Organ Preservation in Rectal Adenocarcinoma trial of 277 rectal cancer patients from April 2014 to March 2020. Based on a post-treatment MRI, patients were classified as having clinical complete response, near-complete clinical response, or incomplete clinical response.
In a five-year follow up, the disease-free survival was 81.8% for participants with clinical complete response, 67.6% for participants with near-complete clinical response and 49.6% for patients with incomplete clinical response.
Findings suggest MRI response categories can be predictive of organ preservation and survival for watch-and-wait rectal cancer patients, according to the study.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
